FDA Approves Iberdomide for Relapsed or Refractory Multiple Myeloma

AIMode News Desk · curated summary

August 15, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA Approves Iberdomide for Relapsed or Refractory Multiple Myeloma Oncology Nursing News

About this story

This story was aggregated from Oncology Nursing News. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

FDA Approves Iberdomide for Relapsed or Refractory Multiple Myeloma

About this story

More in Health

Cancer Research Institute - Including CRI in Your Will Moves Science Forward Giving Patients More Time

Revived rhenium isotope generators answer call for prostate cancer research and other therapies

AACR Invites Early-Career Cancer Researchers to Apply for Professional Excellence Program

Lancaster County cyclists raise more than $16K for cancer research in 500-mile ride